NBRV Nabriva Therapeutics plc

2.88
+0.17  (+6%)
Previous Close 2.72
Open 2.76
Price To Book 2.94
Market Cap 201083698
Shares 69,699,722
Volume 1,009,900
Short Ratio
Av. Daily Volume 1,085,511

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date under priority review August 19, 2019.
Lefamulin - Intravenous and Oral
Moderate to severe Community Acquired Bacterial Pneumonia (CABP)
PDUFA date under priority review April 30, 2019.
Contepo
Complicated urinary tract infections (cUTI)

Latest News

  1. Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
  2. Nabriva Therapeutics to Present Data at ECCMID Demonstrating Potential of Lefamulin for Patients with Community-acquired Bacterial Pneumonia (CABP) and CONTEPO™ (fosfomycin for injection) to Treat Complicated Urinary Tract Infections (cUTIs)
  3. Do Options Traders Know Something About Nabriva Therapeutics (NBRV) Stock We Don't?
  4. Nabriva Therapeutics (NBRV) in Focus: Stock Moves 7.5% Higher
  5. Nabriva Therapeutics to Present at the Needham and Company 18th Annual Healthcare Conference
  6. Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  7. Nabriva Therapeutics Reports 2018 Financial Results and Recent Corporate Highlights
  8. Nabriva Therapeutics Announces Acceptance of New Drug Applications by the FDA for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in Adults
  9. Antimicrobials Working Group Announces Updates to Leadership Team
  10. Nabriva Therapeutics (NBRV) Jumps: Stock Rises 6.7%
  11. Nabriva Therapeutics Announces Webcast of Analyst & Investor Day on January 23, 2019
  12. Nabriva Therapeutics Provides Update on PDUFA Date for Intravenous CONTEPO™
  13. Nabriva Therapeutics Announces Acceptance of the New Drug Application for Intravenous CONTEPO™ to Treat Complicated Urinary Tract Infections by FDA
  14. Antibiotic developer Nabriva enters into $75M loan deal
  15. Nabriva Therapeutics Announces Closing of up to a $75 million Term Loan
  16. Nabriva files 2 NDAs seeking approval for experimental pneumonia treatment
  17. Nabriva Therapeutics Submits New Drug Applications to U.S. Food and Drug Administration for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in Adults
  18. Nabriva Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference
  19. Nabriva Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
  20. Nabriva files new drug application with FDA for urinary tract infection drug